Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

BCX-1777 in Treating Patients With Refractory Cancer


Phase I Pharmacology Study Of Oral And Intravenous BCX-1777 In Patients With Refractory T-Cell And Non-T-Cell Malignancies


BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their growth.


Phase I trial to study the effectiveness of BCX-1777 in treating patients who have refractory cancer.

Study Status: Completed


Condition Intervention Phase
Cancer Drug: forodesine hydrochloride Phase 1

Verified by BioCryst Pharmaceuticals July, 2004

Sponsored by: BioCryst Pharmaceuticals
Information provided by: National Cancer Institute (NCI) identifier: NCT00073944

Study Type: Interventional

Study Design: Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States

Alex Shalaurov, MD, PhD., Study Chair

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site